ELUT Elutia Inc Cumulative Company Assets

Official company branding of Elutia Inc (ELUT)

This price visualization of Elutia Inc. (ELUT) total assets, valued at 43.00, confirms the success of the bio-implant ecosystem for cardiac surgery and plastics with absolute physician loyalty. Elutia Inc. (ELUT) generates revenue from the supply of CanGaroo pouches for pacemaker protection within the regenerative medicine segment. US-based production facilities rely on the use of natural tissues, ensuring a stable output of protective devices.

Company Total Assets: Elutia Inc (ELUT) for 02/21/2024 - 10/29/2026

Financial and market metric breakdowns for Elutia Corp (ELUT)

- share price and expert price forecast:
Price elutia.com|ELUT - Price Target Chart
- market capitalization data:
Market Valuation Elutia Corporation|ELUT - Enterprise Value
- company book value details:
Net Asset Value per Share Elutia|ELUT - Book Capitalization|Capitalization to Book Value Ratio elutia.com|ELUT - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Elutia Inc.|ELUT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Elutia Corporation|ELUT - Company Aggregate Debts|Debts to Book Capitalization Elutia Corporation|ELUT - Company Long-Term Debt|Company Short-Term Debt Elutia|Intermediate Coverage Ratio elutia.com
- company profitability and valuation multiples indicators:
ELUT - Net Profit
Fundamental valuation:Elutia Inc.
Mass-produced product of Elutia Inc.

Total assets, reverse-calculated via ROA, reflect the aggregate value of business resources, where rapid balance sheet growth may signal a risk of inefficient capital freezing. When analyzing the asset history of Elutia Inc. (ELUT), investors should correlate asset dynamics with the capitalization of the company's proprietary technologies, as its unique antibiotic matrices in the medtech niche create a sustainable competitive barrier.

Main competitors

ISRG: Aggregate Business Assets|Aggregate Company Assets Danaher|Cumulative Company Assets BD (BDX)|Company Total Assets STE|WST - Company Assets|Company Total Assets BAX (Baxter International)|MASI: Total Business Assets|Stevanato Group - Company Total Assets|Company Total Asset Base Teleflex Inc. TFX|MMSI: Company Total Assets|Cumulative Company Assets Nobel Biocare|ICUI (ICU Medical, Inc.) - Company Total Assets|Company Total Assets dentsplysirona.com|Aggregate Company Assets LeMaitre Vascular (LMAT)|Aggregate Company Assets ATRC (AtriCure Inc)|STAAR Surgical Corp - Cumulative Company Assets|Aggregate Asset Value NAGE|ZimVie Inc. - Company Total Assets|Company Total Asset Base angiodynamics.com ANGO|Cerus (CERS) - Aggregate Company Assets|Total Business Assets TKNO|Aggregate Company Assets Monogram Technologies Inc|Sharps Tech (STSS) - Company Total Asset Base|Cumulative Company Assets INFU (InfuSystem Holdings)|Aggregate Business Assets UTMD|Aggregate Company Assets KORU Medical KRMD|Aggregate Asset Value NYXH|MBOT: Cumulative Company Assets|PDEX - Company Total Assets|Zentek Ltd. (ZTEK) - Aggregate Company Assets|Cumulative Company Assets milestonescientific.com|NXGL (NEXGEL) - Company Total Assets|Company Assets Retractable Tech RVP|Aggregate Company Assets Harvard Bioscience (HBIO)|Femasys Corporation - Total Business Assets|Meihua Medical Technologies Co., Ltd. - Cumulative Company Assets|Aggregate Business Assets POAI (Predictive Oncology Inc)|CJMB - Aggregate Company Assets|Company Total Asset Base Atrion Corp. ATRI|NURO: Company Total Assets